ClinicalTrials.gg
CompletedNCT01623310Updated Jan 24, 2018Results posted

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

A Phase 3 interventional study of Fluticasone Propionate in Nasal Polyps, sponsored by Optinose US Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
18th of 71
223 · median 60
Started
2013
with 5 others
Phase 3
25 of 83
4 open now
Registered
9th of 83
by date
Lead sponsor
4 of 83
Optinose US Inc.

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 18th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2013, is one of 25 in phase 3, and was the 9th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 12-month open-label treatment phase. The duration of each subject's participation is approximately 53 weeks.

03

Conditions studied

  • Nasal Polyps

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 years and older Women must

    • be practicing an effective method of (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    • be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal ligation at least 1 year before screening) or otherwise be incapable of pregnancy, or
    • be (spontaneous amenorrhea for at least 1 year).
  • Women of must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at the screening visit
  • Have either:

a history of chronic sinusitis with bilateral nasal polyposis determined by nasoendoscopy at screening visit OR a history of chronic sinusitis (without polyps) for equal to or greater than 12 weeks and currently experiencing 2 or more of the following symptoms, one of which MUST be either nasal blockage/congestion or nasal discharge (anterior and/or posterior nasal discharge):

  1. nasal blockage/congestion
  2. nasal discharge (anterior and/or posterior nasal discharge)
  3. facial pain or pressure
  4. reduction or loss of smell

    • Subjects with comorbid asthma or must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral use)within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent; See Attachment 1) for at least 3 months before screening with plans to continue use throughout the study.
    • Must be able to cease treatment with intranasal steroids and inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at the screening visit
    • Must be able to use the OptiNose device correctly; all subjects will be required to demonstrate correct use of the placebo device at the screening visit, see Section 12.1, Visit 1, screening procedures.
    • Must be capable, in the opinion of the investigator, of providing to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Inability to have each nasal cavity examined for any reason, including nasal septum deviation
  • Nasal septum perforation
  • Has had more than 1 episode of epistaxis with frank bleeding in the month before the screening visit
  • Have evidence of significant baseline mucosal injury, ulceration or erosion (eg, exposed cartilage, perforation) on baseline nasal examination/nasoendoscopy
  • History of sinus or nasal surgery within 6 months before the screening visit
  • Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  • Have significant oral structural abnormalities, eg, a cleft palate
  • Diagnosis of cystic fibrosis
  • History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  • Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution
  • Planned sinonasal surgery during the period of the study
  • Allergy, , or to or steroids
  • Allergy or hypersensitivity to any in study drug
  • Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before the screening visit; except as noted in inclusion criteria for subjects with comorbid asthma or
  • Have nasal candidiasis
  • Have taken a potent inhibitor within 14 days before the screening visit; examples of these medications can be found in Section 11.6, Concomitant Medication.
  • History or current diagnosis of any form of glaucoma or ocular hypertension (ie, intraocular pressure >21 mmHg)
  • History of intraocular pressure elevation on any form of steroid therapy
  • History or current diagnosis of the presence (in either eye) of a cataract
  • Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
  • A recent (within 1 year of the screening visit) history of drug or alcohol use, abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
  • Positive urine drug screen at screening visit for drugs of abuse (see Section 14.5), with the exception of prescribed medications for legitimate medical conditions
  • Have participated in a previous clinical trial of OPTINOSE FLUTICASONE
  • Have participated in an drug clinical trial within 30 days of the screening visit
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    OPN-375 400 μg BID

    OPN-375 400 μg BID for 12 months

    Drug: Fluticasone Propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Patients with at least one Adverse Events

    Time frame: 12 Months

Secondary outcomes

  1. Sinonasal Outcome Test 22 (SNOT-22) Total Score

    Change from baseline to Month 3 \& Month 12 in SNOT-22 Total Score SNOT-22 is validated in large populations with chronic sinusitis with and without nasal polyps. The 22 questions are used to calculate a total score (the sum of all items) and 4 subscale scores. The 22 questions are divided among 4 subscales: Rhinologic, Ear and Facial Symptoms, Sleep Function, and Psychological Issues subscales. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be

    Time frame: Baseline, Month 3, Month 12

  2. Lund-Mackay Total Score

    Change from baseline to Month 3, Month 12, in Lund-Mackay Total Score Lund-Mackay Assessment of nasal cavity appearance, via nasoendoscopy, used to evaluate signs of edema, discharge, crusting, scarring/adhesions, and nasal polyps, with each sign rated on a 0 to 2 scale 0: None 2: Worse outcome

    Time frame: Baseline, Month 3, Month 12

  3. Patient Global Impression of Change (PGIC)

    The PGIC took less than 1 minute to complete. Subjects answered question, "Since starting the study drug, how would you rate the change in your symptoms?" Patients may answer very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data listed below reports the total number of patients who answered very much improved, much improved, or minimally improved at the specified time.

    Time frame: Baseline, Month 3, Month 12

  4. Summed Bilateral Nasal Polyp Grading Scale Score

    In subjects with nasal polyps, polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis: large polyps reaching below the lower inferior border of the inferior turbinate

    Time frame: Baseline, Month 3, Month 12

  5. Nasal Polyp Surgery Eligibility

    Time frame: Baseline, Month 3, Month 12

07

Results

Posted Jan 24, 2018

Participant flow

Participant flow — Overall Study
MilestoneOPN-375 400 μg
Started223
Completed144
Not completed79
Withdrew: Adverse event21
Withdrew: Lost to follow-up18
Withdrew: Lack of efficacy6
Withdrew: Protocol violation6
Withdrew: Withdrawal by subject25
Withdrew: Became potentially child-bearing1
Withdrew: Diagnoses of bilateral cateracts1
Withdrew: Investigators discretion-noncompliant1

Outcome measures

PrimaryAdverse Events

Patients with at least one Adverse Events

Time frame:
12 Months
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsOPN-375 400 μg
Adverse Events169
SecondarySinonasal Outcome Test 22 (SNOT-22) Total Score

Change from baseline to Month 3 \& Month 12 in SNOT-22 Total Score SNOT-22 is validated in large populations with chronic sinusitis with and without nasal polyps. The 22 questions are used to calculate a total score (the sum of all items) and 4 subscale scores. The 22 questions are divided among 4 subscales: Rhinologic, Ear and Facial Symptoms, Sleep Function, and Psychological Issues subscales. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be

Time frame:
Baseline, Month 3, Month 12
Reported as:
Mean · units on a scale
Sinonasal Outcome Test 22 (SNOT-22) Total Score
units on a scaleOPN-375 400 μg
Change from BL to Month 3, Pts With Polyps-16.7 ± 15.39
Change from BL to Month 3, Pts Without Polyps-18.6 ± 20.06
Change from BL to Month 12, Pts With Polyps-21.5 ± 21.81
Change from BL to Month 12, Pts Without Polyps-21.1 ± 22.96
SecondaryLund-Mackay Total Score

Change from baseline to Month 3, Month 12, in Lund-Mackay Total Score Lund-Mackay Assessment of nasal cavity appearance, via nasoendoscopy, used to evaluate signs of edema, discharge, crusting, scarring/adhesions, and nasal polyps, with each sign rated on a 0 to 2 scale 0: None 2: Worse outcome

Time frame:
Baseline, Month 3, Month 12
Reported as:
Mean · units on a scale
Lund-Mackay Total Score
units on a scaleOPN-375 400 μg
Change from BL to Month 3, Pts With Polyps-0.8 ± 1.35
Change from BL to Month 3, Pts Without Polyps-0.8 ± 1.21
Change from BL to Month 12, Pts With Polyps-0.7 ± 1.63
Change from BL to Month 12, Pts Without Polyps-0.8 ± 1.18
SecondaryPatient Global Impression of Change (PGIC)

The PGIC took less than 1 minute to complete. Subjects answered question, "Since starting the study drug, how would you rate the change in your symptoms?" Patients may answer very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data listed below reports the total number of patients who answered very much improved, much improved, or minimally improved at the specified time.

Time frame:
Baseline, Month 3, Month 12
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC)
ParticipantsOPN-375 400 μg
Month 3, Pts With Polyps27
Month 3, Patients Without Polyps151
Month 12, Pts With Polyps22
Month 12, Pts Without Polyps110
SecondarySummed Bilateral Nasal Polyp Grading Scale Score

In subjects with nasal polyps, polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis: large polyps reaching below the lower inferior border of the inferior turbinate

Time frame:
Baseline, Month 3, Month 12
Reported as:
Mean · units on a scale
Summed Bilateral Nasal Polyp Grading Scale Score
units on a scaleOPN-375 400 μg
Month 32.0 ± 1.81
Month 121.3 ± 1.19
SecondaryNasal Polyp Surgery Eligibility
Time frame:
Baseline, Month 3, Month 12
Reported as:
Count of participants · Participants
Nasal Polyp Surgery Eligibility
ParticipantsOPN-375 400 μg
Month 3, Pts With Polyps5
Month 3, Patients Without Polyps2
Month 12, Pts With Polyps1
Month 12, Pts Without Polyps3

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone0/223 (0%)0/223 (0%)169/223 (75.8%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventFluticasone
Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders39/223
Epistaxis Identified via Nasal EndoscopyRespiratory, thoracic and mediastinal disorders37/223
Nasal Septum DisorderRespiratory, thoracic and mediastinal disorders32/223
Acute SinusitisInfections and infestations31/223
Spontaneously Reported EpistaxisRespiratory, thoracic and mediastinal disorders25/223
Nasal Septum UlcerationRespiratory, thoracic and mediastinal disorders25/223
HeadacheNervous system disorders21/223
Upper Respiratory Tract InfectionInfections and infestations17/223
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders8/223
CoughRespiratory, thoracic and mediastinal disorders7/223

Baseline characteristics

Age, Continuous
Age, Continuous(years)OPN-375 400 μg
Mean45.4 ± 12.62
Sex: Female, Male
Sex: Female, Male(Participants)OPN-375 400 μg
Female96
Male127
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OPN-375 400 μg
White175
Black/African American45
Asian2
Other1
Region of Enrollment
Region of Enrollment(Participants)OPN-375 400 μg
United States223
Use of ICS treatment for polyps in past 10 years
Use of ICS treatment for polyps in past 10 years(Participants)OPN-375 400 μg
Count of participants214
Previous polyp removal surgery via polypectomy only
Previous polyp removal surgery via polypectomy only(Participants)OPN-375 400 μg
Count of participants11
Previous sinus surgery for polyp removal or sinus surgery
Previous sinus surgery for polyp removal or sinus surgery(Participants)OPN-375 400 μg
Count of participants80
Sinonasal Outcome Test 22 (SNOT-22) Total Score
Sinonasal Outcome Test 22 (SNOT-22) Total Score(units on a scale)OPN-375 400 μg
Pts With Polyps41.9 ± 23.27
Pts Without Polyps39.7 ± 21.72

3 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • Achieve Clinical Research
    Birmingham, Alabama 35216, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Sneeze Wheeze and Itch Associates
    Normal, Illinois 61761, United States
  • Professional Research Network of Kansas
    Wichita, Kansas 67203, United States
  • Best Clinical Trials
    New Orleans, Louisiana 70115, United States
  • PMG Research of Winston Salem
    Winston-Salem, North Carolina 27103, United States
  • HCCA Clinical Research Solutions
    Middleburg Heights, Ohio 44130, United States
  • Allergy and Asthma Research Group
    Eugene, Oregon 97401, United States
  • Clinical Research Solutions
    Franklin, Tennessee 37064, United States
  • William Blake Partners
    Grapevine, Texas 76051, United States
  • Focus Clinical Research
    Draper, Utah 84020, United States
  • InterMountain Ear Nose and Throat
    Salt Lake City, Utah 84102, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Premier Clinical Research
    Spokane, Washington 99204, United States
  • Exemplar Research
    Fairmont, West Virginia 26554, United States
  • Allergy Asthma and Sinus Center
    Greenfield, Wisconsin 53228, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Aug 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 2 years 5 months after primary completion. A results delay was requested in Jul 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2012
First posted
Jun 19, 2012
Start
Sep 2013
Primary completionActual
Aug 2015
CompletionActual
Oct 2015
Results delay requested
Jul 25, 2016
Results first posted
Jan 24, 2018
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01623310
Lead sponsor
Optinose US Inc.
Responsible party
Sponsor
First posted
Jun 19, 2012
Start date
Sep 2013
Primary completion
Aug 2015
Completion
Oct 2015
Results posted
Jan 24, 2018
Last update
Jan 24, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion